The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia
View abstract on PubMed
Summary
This summary is machine-generated.Podocyte damage in nephrotic syndrome elevates PCSK9 (proprotein convertase subtilisin/kexin type 9), a key cholesterol regulator. Inhibiting PCSK9 may offer new treatments for hypercholesterolemia in these patients.
Area Of Science
- Nephrology
- Cardiovascular Research
- Molecular Biology
Background
- Nephrotic syndrome causes severe hypercholesterolemia due to podocyte damage.
- Novel therapeutic targets for this condition are urgently needed.
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of plasma cholesterol.
Purpose Of The Study
- To investigate the role of PCSK9 in mediating hypercholesterolemia associated with nephrotic syndrome.
- To determine if PCSK9 inhibition could be a therapeutic strategy.
Main Methods
- Studied PCSK9 and plasma lipids in nephrotic syndrome patients before and after remission.
- Utilized mouse models: genetically modified podocyte-ablated mice (Pod-ATTAC) and nephrotoxic serum (NTS)-treated mice.
- Examined hepatic PCSK9 deletion in NTS-treated mice to assess PCSK9's contribution to dyslipidemia.
Main Results
- Nephrotic syndrome patients showed decreased plasma cholesterol and PCSK9 upon remission.
- Pod-ATTAC and NTS-treated mice exhibited hypercholesterolemia with significantly increased plasma PCSK9.
- Hepatic PCSK9 knockout mice treated with NTS showed reduced plasma cholesterol and triglycerides, and normalized LDL-associated cholesterol.
Conclusions
- Podocyte injury in nephrotic syndrome leads to increased plasma PCSK9.
- PCSK9 knockout ameliorates dyslipidemia in a mouse model of nephrotic syndrome.
- PCSK9 inhibitors represent a potential therapeutic avenue for nephrotic syndrome-associated hypercholesterolemia.